| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology, and Genetics |
1 Department of Pathology, University of Florida, Jacksonville, Florida; 2 Department of Pathology and 3 Rebecca and John Moores Cancer Center, University of California, San Diego, La Jolla, California; 4 Fred Hutchinson Cancer Research Center, Seattle, Washington; 5 Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts; and 6 Laboratory of Experimental Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
Requests for reprints: Steve Goodison, Department of Pathology, University of Florida Health Science Center, Shands Hospital, 655 West 8th Street, Jacksonville, FL 32209-6511. Phone: 904-244-4220; Fax: 904-244-4290; E-mail: steve.goodison{at}jax.ufl.edu.
The identification of molecular signatures characteristic of tumor cells that are capable of metastatic spread is required for the development of therapeutic interventions to abrogate this lethal process. To facilitate this, we have previously characterized an experimental system in which the role of candidate metastasis-related genes can be screened and tested. Monoclonal cell lines M4A4 and NM2C5 are spontaneously occurring sublines of the MDA-MB-435 cell breast tumor cell line that exhibit phenotypic differences in growth, invasion, and metastatic efficiency in athymic mice. In this study, transcriptional profiles of these cell lines were created using oligonucleotide microarrays representing over 12,000 genes. Intensity modeling and hierarchical clustering analysis identified a 171-gene expression signature that correlated with metastatic phenotype and highlighted several GTPase signaling components. Restoration of one of these GTPases, deleted in liver cancer-1 (DLC-1), in metastatic M4A4 cells to levels observed in the nonmetastatic NM2C5 cell line resulted in the inhibition of migration and invasion in vitro and a significant reduction in the ability of these cells to form pulmonary metastases in athymic mice. These studies show the utility of expression profiling, in an appropriate experimental system, to identify genetic determinants of metastatic sufficiency. The finding that DLC-1 can act as a metastasis-suppressor gene supports an influential role for GTPase signaling in tumor progression.
This article has been cited by other articles:
![]() |
P. Erlmann, S. Schmid, F. A. Horenkamp, M. Geyer, T. G. Pomorski, and M. A. Olayioye DLC1 Activation Requires Lipid Interaction through a Polybasic Region Preceding the RhoGAP Domain Mol. Biol. Cell, October 15, 2009; 20(20): 4400 - 4411. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Zhong, J. Zhang, S. Yang, U. J. K. Soh, J. P. Buschdorf, Y. T. Zhou, D. Yang, and B. C. Low The SAM domain of the RhoGAP DLC1 binds EF1A1 to regulate cell migration J. Cell Sci., February 1, 2009; 122(3): 414 - 424. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-C. Chao, S.-H. Pan, S.-C. Yang, S.-L. Yu, T.-F. Che, C.-W. Lin, M.-S. Tsai, G.-C. Chang, C.-H. Wu, Y.-Y. Wu, et al. Claudin-1 Is a Metastasis Suppressor and Correlates with Clinical Outcome in Lung Adenocarcinoma Am. J. Respir. Crit. Care Med., January 15, 2009; 179(2): 123 - 133. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-p. Wu, Y.-l. Jin, Y.-f. Shang, Z. Jin, P. Wu, and P.-l. Huang Restoration of DLC1 Gene Inhibits Proliferation and Migration of Human Colon Cancer HT29 Cells Ann. Clin. Lab. Sci., January 1, 2009; 39(3): 263 - 269. [Abstract] [Full Text] [PDF] |
||||
![]() |
R.-P. Scholz, J. Regner, A. Theil, P. Erlmann, G. Holeiter, R. Jahne, S. Schmid, A. Hausser, and M. A. Olayioye DLC1 interacts with 14-3-3 proteins to inhibit RhoGAP activity and block nucleocytoplasmic shuttling J. Cell Sci., January 1, 2009; 122(1): 92 - 102. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Y. Kim, K. D. Healy, C. J. Der, N. Sciaky, Y.-J. Bang, and R. L. Juliano Effects of Structure of Rho GTPase-activating Protein DLC-1 on Cell Morphology and Migration J. Biol. Chem., November 21, 2008; 283(47): 32762 - 32770. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Holeiter, J. Heering, P. Erlmann, S. Schmid, R. Jahne, and M. A. Olayioye Deleted in Liver Cancer 1 Controls Cell Migration through a Dia1-Dependent Signaling Pathway Cancer Res., November 1, 2008; 68(21): 8743 - 8751. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-Z. Pang, L.-X. Qin, N. Ren, Z.-Y. Hei, Q.-H. Ye, W.-D. Jia, B.-S. Sun, G.-L. Lin, D.-Y. Liu, Y.-K. Liu, et al. Loss of Heterozygosity at D8S298 Is a Predictor for Long-term Survival of Patients with Tumor-Node-Metastasis Stage I of Hepatocellular Carcinoma Clin. Cancer Res., December 15, 2007; 13(24): 7363 - 7369. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Shutes, C. Onesto, V. Picard, B. Leblond, F. Schweighoffer, and C. J. Der Specificity and Mechanism of Action of EHT 1864, a Novel Small Molecule Inhibitor of Rac Family Small GTPases J. Biol. Chem., December 7, 2007; 282(49): 35666 - 35678. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Qian, G. Li, H. K. Asmussen, L. Asnaghi, W. C. Vass, R. Braverman, K. M. Yamada, N. C. Popescu, A. G. Papageorge, and D. R. Lowy Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities PNAS, May 22, 2007; 104(21): 9012 - 9017. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-C. Liao, L. Si, R. W. deVere White, and S. H. Lo The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1 J. Cell Biol., January 1, 2007; 176(1): 43 - 49. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Sun, S. Goodison, J. Li, L. Liu, and W. Farmerie Improved breast cancer prognosis through the combination of clinical and genetic markers Bioinformatics, January 1, 2007; 23(1): 30 - 37. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. P. Yam, F. C. F. Ko, C.-Y. Chan, D.-Y. Jin, and I. O.-L. Ng Interaction of Deleted in Liver Cancer 1 with Tensin2 in Caveolae and Implications in Tumor Suppression. Cancer Res., September 1, 2006; 66(17): 8367 - 8372. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Guan, X. Zhou, N. Soulitzis, D. A. Spandidos, and N. C. Popescu Aberrant Methylation and Deacetylation of Deleted in Liver Cancer-1 Gene in Prostate Cancer: Potential Clinical Applications Clin. Cancer Res., March 1, 2006; 12(5): 1412 - 1419. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |